Compare SSTK & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SSTK | DRUG |
|---|---|---|
| Founded | 2003 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Pharmaceuticals and Biotechnology |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 596.1M | 707.1M |
| IPO Year | 2012 | 2020 |
| Metric | SSTK | DRUG |
|---|---|---|
| Price | $16.75 | $74.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $25.00 | ★ $129.25 |
| AVG Volume (30 Days) | ★ 241.6K | 174.6K |
| Earning Date | 04-28-2026 | 05-15-2026 |
| Dividend Yield | ★ 8.61% | N/A |
| EPS Growth | ★ 23.76 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.35 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.36 | $23.18 |
| 52 Week High | $29.50 | $123.75 |
| Indicator | SSTK | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 48.64 | 34.43 |
| Support Level | $15.88 | $69.83 |
| Resistance Level | $17.67 | $77.01 |
| Average True Range (ATR) | 0.61 | 4.88 |
| MACD | -0.03 | -1.82 |
| Stochastic Oscillator | 56.54 | 11.47 |
Shutterstock Inc is a U.S.-based company that is engaged in the provision of digital content. The content segment, whose offerings include licenses for Images, Footage, Music, 3 Dimensional, and Generative AI content. Data, Distribution, and Service offerings address customer demand for products and services that are beyond its Content licenses. The company generates the majority of its revenue from Content offerings. Geographically the company generates the majority of its revenue from the Domestic market, but also has its presence in Europe and Rest of the Countries.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.